Peptide Compass
Explore/LL-37

LL-37

Fat Loss / Metabolic • Peptide

◐ Emerging EvidenceResearch Only
Evidence
Weak3/10
Hype
Moderate4/10
Risk
Low3/10
Beginner Friendly
Weak2/10

Plain English Summary

LL-37 is a human cathelicidin antimicrobial peptide involved in immune responses, showing properties of both antimicrobial activity and cytotoxicity towards host cells. It has been implicated in various physiological and pathophysiological processes, including immune activation and inflammation.

What People Use It For

Enhance immune responseAntimicrobial activitySupport bone healthPossibly influence inflammation

Side Effects & Risks

Common Side Effects

Cytotoxicity to osteoblasts at high concentrationsPotential inflammatory responses

References

  • 1https://pubmed.ncbi.nlm.nih.gov/38642493/
  • 2https://pubmed.ncbi.nlm.nih.gov/35649354/
  • 3https://pubmed.ncbi.nlm.nih.gov/35954305/
  • 4https://pubmed.ncbi.nlm.nih.gov/39170953/
  • 5https://pubmed.ncbi.nlm.nih.gov/36769137/
  • 6https://pubmed.ncbi.nlm.nih.gov/36763254/
  • 7https://pubmed.ncbi.nlm.nih.gov/36781570/
  • 8https://pubmed.ncbi.nlm.nih.gov/36294968/

Researchers also explore

Glucose-dependent Insulinotropic Polypeptide (GIP) Profile

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone important for maintaining glucose tolerance. Recent research indicates potential therapeutic use in obesity, diabetes, and other conditions due to its multifaceted metabolic effects.

View

Gastric Inhibitory Polypeptide (GIP) Profile

Gastric Inhibitory Polypeptide (GIP) is an incretin hormone that plays a crucial role in glucose homeostasis by stimulating insulin secretion from pancreatic β cells, enhancing fat deposition, and influencing appetite regulation and bone metabolism. GIP demonstrates distinct physiological effects compared to another incretin, GLP-1, particularly in the context of type 2 diabetes.

View

Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.

View

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.

View

Researcher Sentiment

No votes yet — be the first

Educational Content Only

This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.